Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Overview of the BCR Pathway and BTK in Tumor Development (15 minutes)
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: September 16, 2020 Expiration: September 15, 2021
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca
Danielle Brander, MD
Nicole Lamanna, MD
Jeff P. Sharman, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate differences among agents targeting BTK in terms of molecular characteristics, selectivity, preclinical data, approved indications, dosing, safety profile, and efficacy
  • Delineate the variables to be considered in selecting treatment for CLL including tumor characteristics such as biomarkers and patient characteristics and preferences
  • Describe clinical trial results providing evidence for the important role of BTK inhibitor–based combinations in first-line treatment of CLL including phase III and phase II trials
  • Select patients most likely to benefit from continuous first-line treatment options and those patients most likely to benefit from time-limited first-line options
  • Plan optimal, individualized therapeutic strategies for patients with CLL taking into consideration recent practice-changing clinical trial results
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, quality of life, and continuation of treatment
  • Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) to aid clinical trial enrollment and predict new options in the clinic

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Jeff P. Sharman, MD

Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, Genentech, Gilead Sciences, Pharmacyclics, and TG Therapeutics and consulting fees from AbbVie, AstraZeneca, Genentech, Pharmacyclics, and TG Therapeutics.
Danielle Brander, MD

Assistant Professor of Medicine
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

Danielle M. Brander, MD, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Genentech, Pharmacyclics, Pfizer, Teva, and Verastem; funds for research support (paid to her institution) from AbbVie, ArQule, Ascentage, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, DTRM, Genentech, Juno, MEI Pharma, Pharmacyclics, TG Therapeutics, Tolero, and Verastem; and non-CME/CE fees from AbbVie, ArQule, Genentech, Pfizer, TG Therapeutics, and Verastem.
Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, BeiGene, Celgene, Genentech, Gilead Sciences, Janssen, and Juno and funds for research support from AbbVie, AstraZeneca, BeiGene, Genentech, Juno, Loxo, MingSight, Oncternal, TG Therapeutics, and Verastem.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed that his spouse has ownership interest in AstraZeneca.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hematologists, hematologist-oncologists, and other clinicians involved in the management of patients with CLL and other B-cell malignancies.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate BTK inhibitors into the treatment of patients with CLL.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 16, 2020, through September 15, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Overview of the BCR Pathway and BTK in Tumor Development (15 minutes)
  • CME

Jeff P. Sharman, MD, presents the relationship between the BCR pathway and BTKs in the development of CLL.
Danielle Brander, MD
Nicole Lamanna, MD
Jeff P. Sharman, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: September 16, 2020 Expiration: September 15, 2021

This program is divided into several short segments which you can step through using the Video Chapters widget.
PreviousNext

Related Content

Preview expert ITP abstract selections from ASH 2020 as part of conference coverage from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: November 24, 2020

CCO commentary from Shaji Kumar, MD, on key issues in the management of multiple myeloma

Shaji Kumar, MD Released: November 23, 2020

Expert commentary from Clinical Care Options (CCO) on challenges in diagnosing and treating patients with myelodysplastic syndromes (MDS)

Rami S. Komrokji, MD Released: November 20, 2020

Enter the characteristics of your patient with CLL into this online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Jeff P. Sharman, MD
Program Director
Released: November 20, 2020

Video Chapters


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue